A chemically stable analogue, 9 beta‐methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man

• Published in: British journal of clinical pharmacology Vol. 18; no. 6; pp. 921 - 933
• Main Authors: O'Grady, J, Hedges, A, Whittle, BJ, Al‐Sinawi, LA, Mekki, QA, Burke, C, Moody, SG, Moti, MJ, Hassan, S
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-12-1984
• Subjects: 1-Methyl-3-isobutylxanthine - pharmacology; Adenosine Diphosphate - pharmacology; Adult; Arachidonic Acid; Arachidonic Acids - blood; Arachidonic Acids - pharmacology; Bleeding Time; Blood Coagulation - drug effects; Blood Platelets - metabolism; Collagen - pharmacology; Cyclic AMP - blood; Epoprostenol - pharmacology; Hemodynamics - drug effects; Humans; In Vitro Techniques; Infusions, Parenteral; Male; Platelet Aggregation - drug effects
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.1984.tb02565.x

The effects of 9 beta‐methyl carbacyclin, a chemically stable analogue of epoprostenol (prostacyclin, PGI2) were studied, in comparison with epoprostenol, both in vitro and in vivo in man. In vitro 9 beta‐methyl carbacyclin and epoprostenol inhibited platelet aggregation induced by ADP, collagen, the endoperoxide analogue U46619 and arachidonic acid. The potency of 9 beta‐methyl carbacyclin relative to epoprostenol was comparable in ADP and collagen‐aggregated platelet rich plasma (PRP), 9 beta‐methyl carbacyclin being 0.01 times as active as epoprostenol. The anti‐aggregatory potencies of the two compounds were comparable in PRP and whole blood. The phosphodiesterase inhibitor isobutyl methyl xanthine enhanced the anti‐aggregatory activity of both compounds in vitro. 9 beta‐methyl carbacyclin and epoprostenol elevated platelet cyclic AMP, 9 beta‐methyl carbacyclin being 0.04 times as active as epoprostenol. In a placebo controlled trial both drugs produces significant headache and facial flushing when compared with placebo. Nasal stuffiness, abdominal discomfort and nausea were reported on all three treatments. Both drugs caused significant and comparable increase in heart rate and decrease in pre‐ejection (PEP) and PEP/left ventricular ejection time (LVET) ratio compared with placebo. Systolic and diastolic blood pressure, LVET and QS2 index were unchanged. Platelet aggregation responses to ADP were significantly inhibited by all three doses of both drugs compared with placebo. Bleeding time was significantly longer during epoprostenol infusion than either placebo or 9 beta‐methyl carbacyclin infusion. Neither drug had significant effect, compared with placebo, on kaolin activated clotting time in PPP, PRP or in PRP in the presence of heparin, prothrombin time, partial thromboplastin time, thrombin clotting time, fibrinogen, fibrinogen degradation products or euglobulin clot lysis time. The pharmacodynamic effects and duration of action of 9 beta‐methyl carbacyclin and of epoprostenol are similar; 9 beta‐methyl carbacyclin is approximately 100 times less potent than epoprostenol in man.